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ABSTRACT
Aims An epidemiological study carried out in 2006
indicated a high prevalence of blinding trachoma in the
Kolofata Health District, Far North Region, Republic of
Cameroon. As a result, the national blindness control
programme of Cameroon instituted a trachoma
elimination programme using the SAFE strategy.
Methods A campaign to treat the entire district
population with azithromycin 1.5% eye drops was
undertaken in February 2008. To measure the
effectiveness of treatment on the prevalence of active
trachoma, two epidemiological studies were conducted
on a representative sample of children aged between 1
and 10 years. The ﬁrst study was performed just prior to
the treatment campaign and the second study was
performed 1 year later.
Results The prevalence of active forms of trachoma
(trachomatous inﬂammationdfollicular (TF) + TF/
trachomatous inﬂammationdintense (TI)) dropped from
31.5 (95% CI 26.4 to 37.5)% before treatment to 6.3
(95% CI 4.1 to 9.6)% 1 year after treatmentda reduction
of nearly 80%. There were no reports of serious or
systemic side effects. Tolerance was excellent and no
treatment was interrupted.
Conclusion Mass treatment with azithromycin 1.5% eye
drops is feasible, well tolerated and effective.
Prevention of blindnessand visual impairment is one
of the public health priorities of the Republic of
Cameroon. The National Blindness Prevention
Programme and a Vision 2020 plan were established
as a result of this policy of prevention. A study to
evaluate the prevalence of active and scarring
trachoma, conducted in December 2006 in the Kolo-
fata Health District (ﬁgure 1), signalled the presence
of endemic trachoma with signiﬁcant blinding
potential.
1 The National Program of Prevention of
Blindness decided to plan a elimination programme
by implementing the SurgeryeAntibioticseFacial
cleanlinesseEnvironmental impact (SAFE) strategy
2
and addressing the “A” (antibiotic) component,
a mass treatment of the entire population of the
district with azithromycin 1.5% eye drops.
The objective of this study was to assess the
feasibility, tolerance and effectiveness of a topical
treatment with azithromycin 1.5% eye drops, used
for the ﬁrst time on a large scale to reduce the prev-
alence of active forms of trachoma in a population.
METHODS
Mass treatment campaign
In accordance with the WHO recommendations,
3
the trachoma control programme in the Kolofata
Health District called for one mass treatment
campaign per year for 3 years. The ﬁrst campaign
began on 23 February 2008 and ended on 10 March
2008.
The target population was all 115 274 residents
of the Kolofata Health District.
4
A total of 120 000 complete treatments (720 000
single doses) of azithromycin 1.5%, donated by
Théa Laboratories (Clermont-Ferrand, France), were
sent by air from Europe to Yaoundé (Cameroon),
and by train from Yaoundé to Kolofata.
A door-to-door strategy was used. In each
compound (group of shelters housing an extended
family), a local community health worker, helped
by a literate second-level community health
worker, performed a census of the entire population
of the neighbourhood or village assigned to the
local community health worker. One census form
was completed for each compound.
Over the following days, an effort was made to
treat the entire population of the district with
azithromycin 1.5% eye drops, one drop in each eye
in the morning and evening for three consecutive
days (six doses). Questionnaires designed to docu-
ment side effects or symptoms of intolerance to the
eye drops were administered and collected daily by
ophthalmology nurses.
In all, 250 local community health workers, 23
second-level community health workers, one head
nurse for each of the seven health centres, two
District Health Service logisticians and four
ophthalmology nurses from the non-governmental
organisation Ophtalmo Sans Frontières were
involved in the campaign. The Kolofata District
Medical Ofﬁcer and an expert from the National
Centre of Ophthalmology of the Quinze Vingts,
Paris, coordinated and supervised all activities
related to training, logistics, education and treat-
ment.
The studies
Two descriptive cross-sectional studies were
conducted in the Kolofata Health District, the ﬁrst
15 days prior to treatment in February 2008 and the
second 1 year after treatment in January 2009.
These studies were performed in order to measure
the effectiveness of treatment on the prevalence of
active forms of trachoma in the population.
Trachomatous inﬂammationdfollicular (TF) and
TF/trachomatous inﬂammationdintense (TI)
forms among children aged between 1 and 10 years
were used as indicators. The standard WHO
protocol for trachoma prevalence surveys was
used.
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Global issuesThe population studied was chosen at random and was based
on the exhaustive list of villages and demographic statistics
gathered in 2006 for the national census.
4
Assuming a prevalence of <5% following the third year of
mass treatment, it was necessary to include 2400 children in the
study to obtain a precision of approximately 1.5% at a bilateral
alpha threshold of 5% and a cluster effect of 4.
6 This would also
allow conclusions to be drawn, in accordance with WHO
recommendations, concerning the interruption of transmission.
3
As a result, 2400 children aged between 1 and 10 years were
divided into 40 clusters, with 60 children per cluster. The WHO
simpliﬁed grading system was used for the recognition and
registering of cases of trachoma.
7
Two teams shared the ﬁeldwork. Each team consisted of
a census nurse and either an ophthalmology nurse or an
ophthalmologist. The same teams and the same ophthalmolo-
gist conducted the before-treatment study and the after-treat-
ment study. A 4-day training session was held for the nurses.
After these training sessions, the inter-observer variation was
very satisfactory (k¼0.81e1.00). Data were compiled and
analysed using EPIINFO 6 software (Centers for Disease Control
and Prevention, Atlanta, Georgia, USA). Estimated CIs took into
account the composition of sample clusters using the Epitable
program from EPIINFO 6.
8
RESULTS
Results of the mass treatment campaign using azithromycin
1.5% eye drops
Each of the 250 local community health workers was assigned
a village or neighbourhood of 400 to 500 residents. During the 15
days preceding the beginning of treatment, the local community
health workers, helped by a literate second-level community
health worker, conducted an exhaustive door-to-door census of
all residents of the Kolofata Health District. The local commu-
nity health workers then administered treatment by visiting
each household in the morning and evening for three consecu-
tive days.
There were 115 274 people counted in the census; community
health workers administered azithromycin 1.5% eye drops (one
drop in each eye in the morning and evening for 3 days) to 111
340 people (coverage 96.6%). The campaign covered the entire
district and lasted 15 days. A total of 51 659 adults and 59 681
children <15 years old were treated (52 866 male and 58 474
female). Two adults refused treatment for personal reasons not
linked to the treatment.
Questionnaires concerning any side effects of treatment were
administered by ophthalmology nurses during daily visits to
assigned villages. Minor complaints were recorded (blurred
vision lasting several minutes following instillation of eye drops
or transient burning sensation in the eyes). No adult requested
that treatment for themselves or their children be interrupted.
There were no reported serious or systemic side effects.
Age and sex distribution of children in the study population aged
between 1 and 10 years
The number of children examined during the study relative to
the number counted in the census is presented in table 1.
Age and sex distributions were similar in the sample popula-
tions before and after treatment (p>0.05) (table 2).
Prevalence of trachoma before and after treatment among
children aged between 1 and 10 years
The prevalence of TF in the study sample was estimated to be 24
(95% CI 20.7 to 27.5)% before treatment and 5.8 (95% CI 4.1 to
8)% after treatment (table 3). The prevalence of TF/TI was
estimated to be 7.5 (95% CI 5.7 to 10)% before treatment and 0.5
(95% CI 0.13 to 1.6)% after treatment (table 3). The prevalence of
active forms (TF + TF/TI) was estimated to be 31.5 (95% CI 26.4
to 37.5)% before treatment and 6.3 (95% CI 4.5 to 8.6)% after
treatment (table 3). The OR for TF before and after treatment
was 5.1 (range 4.2e6.2). The OR was 14 (range 8.1e24) for TI
forms and 6.7 (range 5.6e8.1) for TF + TF/TI forms.
DISCUSSION
There are currently two ways of assessing the epidemiological
situation in a trachoma endemic area: the nucleic acid ampliﬁ-
cation tests and the clinical grading. The WHO trachoma
simpliﬁed grading system is currently the only WHO-recom-
mended system to assess the clinical trachoma prevalence and to
Figure 1 Map of the Republic of Cameroon.
Table 1 Study participation
Examined (n) Counted (n) Participation (%)
Before
treatment
After
treatment
Before
treatment
After
treatment
Before
treatment
After
treatment
Children
aged >1
and <10
years
2517 2404 2570 2411 97.9 99.7
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Global issuesmonitor a trachoma control programme in a community.
9 We
therefore decided to use it to assess the feasibility, tolerance and
effectiveness of a topical treatment with azithromycin 1.5% eye
drops, used for the ﬁrst time on a large scale to reduce the
prevalence of active forms of trachoma in a population.
Feasibility of mass treatment with azithromycin 1.5% eye drops
A high coverage (96.6% of the census population) was obtained
as a result of treatment being administered directly by the health
personnel who participated in the campaign. The campaign
required the mobilisation of all the district’s community health
workers for 15 days. Daily supervision in the ﬁeld as well as high-
quality coordination by the health service authorities were
indispensable, as these prevented interruptions in the supply of
eye drops and assured the daily collection of data relating to
treatment coverage and side effects.
Tolerance of mass treatment with azithromycin 1.5% eye drops
Apart from minor complaints, which did not result in treatment
interruption, treatment was accepted and well tolerated by both
children and adults.
Results of mass treatment with azithromycin 1.5% eye drops
The importance of the endemic trachoma in this district justiﬁed
the mass treatment of the entire district population with
azithromycin 1.5% eye drops as part of the SAFE strategy and in
accordance with WHO recommendations.
3
The reduction of the prevalence of active trachoma among
children is likely to be mainly a result of the mass treatment
with azithromycin 1.5% eye drops. Between the ﬁrst study
conducted in 2006 and the study conducted prior to the ﬁrst
treatment in 2008, there was no signiﬁcant reduction of
trachoma prevalence, which might have been due to a “secular
trend” effect. Between February 2008 and January 2009, the
application of the other components of the SAFE strategy
consisted of the construction of a borehole water pump to
provide safe water in each of three villages and the undertaking of
numerous educational activities to promote individual and
collective hygiene, but it seems unlikely that these other inter-
ventions alone could have produced so large a reduction in
trachoma prevalence in so short a time.
Relative effectiveness of azithromycin 1.5% eye drops and oral
azithromycin
The most common drugs currently used in trachoma mass
treatment campaigns are azithromycin 20 mg/kg taken orally
and tetracycline 1% eye ointment.
In Niger, a mass treatment campaign using oral azithromycin
was conducted in two districts with 72 villages from 2002 to
2005. The prevalence of TF among children decreased from
62.3% and 49.5% to 7.6% and 6.7% in 3 years,
10 a reduction of
89% in one village and 85% in the other. No study was conducted
within the 3-year interval. In Mali, a mass treatment campaign
using oral azithromycin was conducted in seven districts from
2002 to 2005. The prevalence of TF/TI among children decreased
from 33% to 2.5% in 3 years,
11 a reduction of 92.4%.
Since prevalence rates 1 year after treatment with oral
azithromycin are unknown, it is not yet possible to conclude
with certainty that mass treatment with azithromycin 1.5% eye
drops can be considered at least as effective as treatment with
oral azithromycin. We await the results of studies planned for
2010 and eventually 2011 following the third of three consecu-
tive annual treatment campaigns for conﬁrmation.
A clinical trial showed that azithromycin 1.5% twice a day for
3 days has a similar efﬁcacy to a single oral 20 mg/kg dose of
azithromycin for the treatment of active trachoma in children 2
months after treatment.
12 There are no publications on the
relative effectiveness of tetracycline 1% eye ointment and
azithromycin 1.5% eye drops on active trachoma.
Potential advantages of topical azithromycin over topical
tetracycline and oral azithromycin
In 1997, a working paper pointing out the need for a topical treat-
ment was presented at the WHO Alliance for the Global Elimina-
tion of Blinding TrachomabytheYear 2020(GET2020) meeting.
13
This paper also listed the potential advantages of topical
azithromycin over topical tetracycline and oral azithromycin.
In children with active trachoma, topical tetracycline oint-
ment can be difﬁcult to apply and compliance is poor. The
ointment may cause discomfort and blurred vision. Many chil-
dren who are asymptomatic may not continue the topical
treatment, and parents may not be motivated to continue such
therapy. The lack of compliance with topical tetracycline oint-
ment may account for the failure to control trachoma as a major
cause of blindness worldwide.
14
Cases of entropion trichiasis detected during the investigating
teams’ visits to the villages were referred to the ophthalmological
service of the Kolofata District Hospital for free surgery. The
same was true of cases detected by community health workers
during treatment and education campaigns. From January 2007
to December 2008, nearly 1000 eyelids affected by entropion
trichiasis were surgically repaired.
Following encouraging results from the ﬁrst mass treatment
campaign with azithromycin 1.5% eye drops, two additional
mass treatment campaigns were planned. The second campaign
took place in February 2009. A third study to track the evolution
Table 2 Comparison of the distribution of children included in the study
in 2008 and 2009 by age and sex
Variable
Sample
Before treatment After treatment
Age 1e4 years 1391 (55.3) 1332 (55.4)
Age 5e9 years 1126 (44.7) 1072 (44.6)
Male 1280 (50.9) 1236 (51.4)
Female 1237 (49.1) 1169 (48.6)
Total 2517 (100) 2404 (100)
Values are n (%).
Table 3 Prevalence of active trachoma (TF, TF/TI and TF + TF/TI) before and after treatment among
children aged between 1 and 10 years
TF TF/TI TF + TF/TI
n % (95% CI) n % (95% CI) n % (95% CI)
Before treatment 603 24 (20.7 to 27.5) 190 7.5 (5.7 to 10) 793 31.5 (26.4 to 37.5)
After treatment 140 5.8 (4.1 to 8) 14 0.5 (0.13 to 1.6) 154 6.4 (4.5 to 8.6)
TF, trachomatous inﬂammationdfollicular; TI, trachomatous inﬂammationdintense.
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Global issuesof active trachoma prevalence among children is planned for
January 2010 prior to the proposed third mass treatment
campaign.
To reinforce and perpetuate the reduction of trachoma prev-
alence and to advance towards elimination of blinding trachoma
in this area, the other three components of the SAFE strategy
must also be reinforced as recommended by GET 2020.
2
Furthermore, it would be advisable to proceed to a rapid evalu-
ation of the prevalence of trachoma in the North and Far North
Regions in order to understand the geographical extent of the
trachoma endemic in Cameroon. If the endemic is widespread,
the success of this ﬁrst trachoma treatment campaign should
be extended to the entire North and Far North Regions of
Cameroon.
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